Share this article
Share this article
NEW YORK, Feb. 5, 2021 /PRNewswire/ John E. Kehoe, MD, is being recognized by Continental Who s Who as a Top Breast Cancer Surgeon 2021 for his remarkable achievements in the field of Medicine and for his exceptional work ethic as a Breast Cancer Surgeon and Surgical Oncologist with his private practice.
(PRNewsfoto/Continental Who s Who)
Situated at 9711 3rd. Avenue, Dr. John Kehoe Breast Center is an innovative breast center facility in Brooklyn that has provided comprehensive breast medical care from screening and diagnosis to breast cancer treatment. For years, the center has been built on the foundation that every woman should have a specialized breast doctor as she has a gynecologist. Dr. Kehoe and his dedicated staff make themselves available to any woman who is concerned about their findings or what someone else found on the breast exam. Treatment plans are created according to each patient s routine breast
Study shows how tissue damage promotes the earliest stages of pancreatic cancer
Like weeds sprouting from cracks in the pavement, cancer often forms in sites of tissue damage. That damage could be an infection, a physical wound, or some type of inflammation.
Common examples include stomach cancer caused by H. pylori infection, Barrett s esophagus caused by acid reflux, and even smoking-induced lung cancer.
Exactly how tissue damage colludes with genetic changes to promote cancer isn t fully understood. Most of what scientists know about cancer concerns advanced stages of the disease. That s especially true for cancers such as pancreatic cancer that are usually diagnosed very late.
Share this article
Share this article
ROCKLAND, Mass., Feb. 3, 2021 /PRNewswire/ EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the US Food and Drug Administration (FDA) has approved TEPMETKO
® (tepotinib) following Priority Review for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (
MET) exon 14 skipping alterations. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
The approval is based on results from the pivotal Phase II VISION study evaluating TEPMETKO as monotherapy in patients with advanced NSCLC with
New leader will make history as first female president of Wake Forest University Kate Murphy, The News & Observer (Raleigh, N.C.)
Feb. 1 Wake Forest University has announced Susan R. Wente as its first female president, after an international search for a new leader of the private university in Winston-Salem. Dr. Wente is the right person to enable Wake Forest to seize the opportunities before it, said Gerald Roach, chair of the Board of Trustees and search committee that unanimously recommended Wente. Among a field of highly-qualified candidates, she stood out as a transformational leader and world-class academic who is committed to the personal connection and engagement that Wake Forest values, Roach said in a statement.